Blueprint Medicines Corporation (NASDAQ:BPMC) Q2 2024 Earnings Conference Call August 1, 2024 8:00 AM ET
Company Participants
Jenna Cohen - Vice President-Investor Relations
Kate Haviland - Chief Executive Officer
Philina Lee - Chief Commercial Officer
Christy Rossi - Chief Operating Officer
Mike Landsittel - Chief Financial Officer
Fouad Namouni - President-Research & Development
Conference Call Participants
Salveen Richter - Goldman Sachs
Brad Canino - Stifel
Marc Frahm - TD Cowen
Michael Schmidt - Guggenheim
Reni Benjamin - Citizens JMP
Laura Prendergast - Raymond James
Ami Fadia - Needham
Matt Biegler - Oppenheimer
Andy Berens - Leerink
Sudan Loganathan - Stephens
Operator
Hello, everyone. At this time I would like to welcome everyone to the Blueprint Medicines' Second Quarter 2024 Financial Results Conference Call. My name is Bruno and I'll be operating your call today. [Operator Instructions] I'll now hand over to your host Jenna Cohen. Please you may begin your conference.
Jenna Cohen
Thank you, Bruno. Good morning, everyone and welcome to Blueprint Medicines' second quarter 2024 financial and operating results conference call. This morning we issued a press release which outlines the topics we plan to discuss today. You can access the press release as well as the slides that we'll be reviewing by going to the Investor's section of our website at www.blueprintmedicines.com
Joining me today are Kate Haviland, Chief Executive Officer; Philina Lee, Chief Commercial Officer; Christy Rossi, Chief Operating Officer; and Mike Landsittel, Chief Financial Officer. Fouad Namouni, President Research and Development is also on the line and available during Q&A.
Before we begin, I'd like to remind you that some of the statements made during the call today are forward-looking statements as outlined on Slide 3 and are subject to a number of risks and uncertainties. These may cause our actual results to differ materially including those described in our reports filed with the SEC. You are cautioned not to place any undue reliance on these forward-looking statements and Blueprint disclaims any obligation to update such statements.
I'll now hand the call over to Kate.
Kate Haviland
Thank you, Jenna and good morning, everyone. This quarter marks a milestone one full year since the US approval of AYVAKIT for indolent systemic mastocytosis. At the beginning of the year, we laid out that our top priority as a company is AYVAKIT's launch execution. And we have delivered yet another very strong quarter of revenue, one that exceeded our own expectations as we continue to build this new rare disease market. This is one of the most exciting rare disease launches happening today, as each quarter makes AYVAKIT's path to a greater than $2 billion peak revenue opportunity that much clear.